|Title:||Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders|
|Abstract:|| Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).|
|Inventor(s):|| Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Harris; Jeffrey P. (La Jolla, CA), Lebel; Carl (Malibu, CA), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA) |
|Assignee:|| Otonomy, Inc. (San Diego, CA) The Regents of the University of California (Oakland, CA) |
|Filing Date:||Jun 29, 2009|
|Claims:||1. A method of treating an otic disease or condition selected from ear cancer and autoimmune ear disease (AIED) comprising administering to an individual in need thereof an intratympanic composition comprising: between about 0.01% to about 50% by weight of a multiparticulate cytotoxic agent, or pharmaceutically acceptable salt thereof; and a polyoxyethylene-polyoxypropylene copolymer in an amount sufficient to provide a gelation temperature of between about room temperature and about body temperature; wherein the intratympanic composition provides release of the cytotoxic agent into the ear for a period of at least 5 days after a single intratympanic administration provided that the cytotoxic agent is a non-corticosteroid cytotoxic agent. |
2. The method of claim 1, wherein the multiparticulate cytotoxic agent is essentially in the form of micronized particles.
3. The method of claim 1, wherein the cytotoxic agent is selected from an antimetabolite, an antifolate, an alkylating agent and a DNA intercalator.
4. The method of claim 1, wherein the cytotoxic agent is selected from methotrexate, thalidomide, cyclophosphamide, lenalidomide and CC-4047.
5. The method of claim 1, wherein the polyoxyethylene polyoxypropylene copolymer is poloxamer 407.